Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Metodverifiering med KRYPTOR compact PLUS samt fördjupad litteraturgenomgång av förekommande kliniskt biokemiska analysmetoder för Chromogranin A i plasma och serum.
Jönköping University, School of Health and Welfare, HHJ, Dep. of Natural Science and Biomedicine.
Jönköping University, School of Health and Welfare, HHJ, Dep. of Natural Science and Biomedicine.
2016 (Swedish)Independent thesis Basic level (degree of Bachelor), 10 credits / 15 HE creditsStudent thesis
Abstract [sv]

Antal cancerfall ökar ständigt. Samtidigt ses en ökning av antalet cancerpatienter som lever längre tack vare tidig diagnostisering och bättre behandlingsmetoder. Neuroendokrina tumörsjukdomar diagnostiseras med hjälp av tumörmarkören chromogranin A. Syftet med studien var att redogöra för och jämföra kliniskt biokemiska metoder för analys av chromogranin A i plasma och serum. I samband med detta gjordes verifiering av KRYPTOR, BRAHMS automated immunofluorescent assay (KRYPTOR) för chromogranin A. Förekomst av analysmetoder undersöktes genom fördjupad litteraturgenomgång. Metodverifieringen innefattade smittöverföringstest mellan prover, mellanliggande precision, inomserieprecision samt jämförelse med samma metod respektive radioimmunoassay-metoden. I litteraturgenomgången erhölls analysmetoderna radioimmunoassay, immunoradiometric assay, enzymed linked immunosorbent assay och KRYPTOR/immunochemiluminometric assay. Metodverifieringens smittöverföringsrisk blev 0.04%, mellanliggande precision gav total CV på 1.96% respektive 2.33%, inomserieprecisions total CV 2.85%. Fem av sex analysresultat överrensstämde vid jämförelse med radioimmunoassay, medan jämförelse med samma metod gav en genomsnittlig skillnad på 17.6%. Sammanfattningsvis konstaterades att inom forskning används fyra immunologiska metoder för analys av chromogranin A i plasma och serum. Dess utveckling har gått från radioaktiv manuell till icke-radioaktiv automatiserad analysmetod med förkortad analystid. Metodverifieringen med KRYPTOR visade god mellanliggande- och inomserieprecision, men otillräckligt provunderlag resulterade i låg reliabilitet.

Abstract [en]

Title: Verification on KRYPTOR compact PLUS and an in-depth literature overview of clinical biochemical assays for the detection of Chromogranin A in plasma and serum.

 

Cancer is constantly increasing. Simultaneously, there is an increase in survival for cancer patients due to early diagnosis and better treatment.  Neuroendocrine tumour disease is diagnosed with help of tumour marker chromogranin A. The aim of this study was to narrate and compare clinical biochemical methods for the detection of chromogranin A in plasma and serum. In addition, a verification of KRYPTOR, BRAHMS automated immunofluorescent assay (KRYPTOR) for chromogranin A was performed. Occurring methods for analysis was investigated by in-depth literature overview. Verification contained tests for carry over, intra- and inter-assay, comparison with same method and radioimmunoassay method respectively. The literature overview resulted in radioimmunoassay, immunoradiometric assay, enzyme linked immunosorbent assay and KRYPTOR/immunochemiluminometric assay. Verification gave carry over 0.04%, inter-assay CV 1.96% and 2.33%, intra-assay CV 2.85%. Comparison with the same method gave a mean difference of 17.6% and five samples out of six correlated for comparison with radioimmunoassay. In summary, four immunological methods are used for analysis of chromogranin A, within research. Their development ranges from radioactive manual to non-radioactive automated method with shortened analysis times. Verification for KRYPTOR showed god intra- and inter-assay but an insufficient number of samples resulted in low reliability.

Place, publisher, year, edition, pages
2016. , 59 p.
Keyword [en]
CGA, tomour marker, blood, human, neuroendocrine tumours
Keyword [sv]
CGA, tumörmarkör, blod, human, neuroendokrina tumörer
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:hj:diva-30872ISRN: JU-HHJ-BLA-1-20160027OAI: oai:DiVA.org:hj-30872DiVA: diva2:942765
Subject / course
HHJ, Biomedical Laboratory Science
Presentation
2016-06-08, Länssjukhuset Ryhov, konferensrum kolven, Jönköping, 21:15 (Swedish)
Supervisors
Examiners
Available from: 2016-06-28 Created: 2016-06-26 Last updated: 2016-06-28Bibliographically approved

Open Access in DiVA

fulltext(6142 kB)88 downloads
File information
File name FULLTEXT01.pdfFile size 6142 kBChecksum SHA-512
8ccdea2aeec063f80e9dd93a5ef56c78235dc7ef270c4c340dc680b5f008db878b972175ba9db1c79e2abaedb330924aafd6a70bebb768891b61fcd23841fc09
Type fulltextMimetype application/pdf

By organisation
HHJ, Dep. of Natural Science and Biomedicine
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 88 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

urn-nbn

Altmetric score

urn-nbn
Total: 96 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf